Our Technology
Our strategic approach is anchored in the development of a patient-specific, rare-disease induced pluripotent stem cell (iPS) BioBank. This state-of-the-art initiative, at the vanguard of biotechnology and personalized medicine, represents a significant stride in a rapidly evolving field.
Further, we are propelling the development of Idolyon(TM), our proprietary cardiac and neuromuscular organoids derived from iPS. These disease-relevant organoids serve as personalized, non-invasive platforms for drug screening, enabling us to customize treatments to the unique needs of individual patients. This innovative approach signifies a substantial leap forward in patient care and a promising advancement in the realm of personalized medicine.
Leading our therapeutic pipeline is KB-001(TM), a therapy based on repurposing an FDA-approved drug to activate a developmental signaling pathway relevant to FRDA. This strategic approach not only expedites the path to treatment but also reduces potential risks by leveraging existing approved drugs.
In addition, KosBio is advancing the development of a series of novel, patented drugs (KB002-KB021). These drugs are projected to have significantly greater potency than KB-001(TM), marking a substantial advancement in our therapeutic arsenal.
